🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSurvodutide SYNCHRONIZE Phase 3 — November 2025 Page 8

Survodutide SYNCHRONIZE Phase 3 — November 2025

ZaraB_AL Thu, Sep 12, 2024 at 4:18 AM 56 replies 2,243 viewsPage 8 of 12
denise_HTX
Member
145
678
Jan 2025
Houston, TX
Jan 15, 2025 at 12:58 AM#36
PeptideChemSF said:
Practical: whatever you change, write down the date and the reason.

Agreed, with the usual condition: that holds for the average and this board is a collection of individuals. A population claim and a personal prediction are different things and get quoted interchangeably.

21 19sarah.morrison, NeuroNate, JessicaH_TX and 18 others
Reply Quote Save Share Report
MeganSA_TX
Member
634
2,890
Jun 2024
San Antonio, TX
Jan 21, 2025 at 11:49 PM#37
PeptideChemSF said:
Practical: whatever you change, write down the date and the reason.

Genuinely useful, thank you. I had the facts and not the framework. I will report back once I have actually tried it.

Last edited: Jan 22, 2025 at 1:49 AM
22 20julia.endo, JessicaM_2024, TomFromTexas and 19 others
Reply Quote Save Share Report
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
Jan 28, 2025 at 10:36 PM#38

From the other side of the consultation, briefly. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

That is the short version; the long version is somebody else's post.

23 21TomFromTexas, mike.trainer_LA, sarah_nash92 and 20 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
maya_sedona
Member
289
1,234
Sep 2024
Sedona, AZ
Feb 4, 2025 at 9:19 PM#39
Dr.KarenChen said:
Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…

This is my experience too, for whatever a second data point is worth.

24 22MikeKY_noInsulin, Dr.RaviCardio, jennifer_SEA and 21 others
Reply Quote Save Share Report
nick_SD_fit
Member
278
1,234
Sep 2024
San Diego, CA
Feb 11, 2025 at 7:58 PM#40
Dr.KarenChen said:
Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…

Coming at Dr.KarenChen’s question from a different direction. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.

46 19SurmountFan_IN, PeptideChemSF, A1cHero_PHX and 43 others
Reply Quote Save Share Report
167891012

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register